News & Views

Telix is pleased to provide details of BioSpectrum Asia interview with Telix Japan President & COO Dr Shintaro Nishimura on the APAC oncology market & opportunities/challenges in the Japanese market for radiopharmaceutical products.

Telix Pharmaceuticals Limited is delighted to announce the appointment of Ms. Odile Jaume as President and Chief Operating Officer (COO) of Telix’s European operations.

Telix Pharmaceuticals Limited is pleased to announce the establishment Telix Pharmaceuticals (Japan) Ltd and appointment of the first two members of the Japanese leadership team.

Telix has today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK)

Telix has today announced the appointment of Dr. Bernard Lambert as President and Chief Operating Officer (COO) of Telix’s US subsidiary.

Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported by institutional investors internationally and domestically, as well as by retail investors in Australia.

Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA (ANMI).

Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50 million.

Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of Melbourne.

Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public Offering.